ResearcherUniversity of California San DiegoActive in the last 2 years
Kevin Christian Montecillo Gulay
Matched on ORCID iD 0000-0002-9568-3590; OpenAlex author ID A5041073957, A5159172594. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers
Papers 4
- ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC. Co-author DOI 10.1038/s41589-025-01978-1↗
- Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.09.027↗
- MICAL2 Promotes Pancreatic Cancer Growth and Metastasis. Co-author DOI 10.1158/0008-5472.can-24-0744↗
- Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-23-1313↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hervé Tiriac · 4 shared papers, 2023–2026 · strength 0.76
- Paper ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC. DOI 10.1038/s41589-025-01978-1↗
- Paper Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. DOI 10.1053/j.gastro.2026.09.027↗
- Paper MICAL2 Promotes Pancreatic Cancer Growth and Metastasis. DOI 10.1158/0008-5472.can-24-0744↗
- Andrew M. Lowy · 3 shared papers, 2023–2026 · strength 0.56
- Paper ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC. DOI 10.1038/s41589-025-01978-1↗
- Paper MICAL2 Promotes Pancreatic Cancer Growth and Metastasis. DOI 10.1158/0008-5472.can-24-0744↗
- Paper Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/0008-5472.can-23-1313↗
- Nathan L. Tran · 1 shared paper, 2026 · strength 0.24
- Fleur M. Ferguson · 1 shared paper, 2026 · strength 0.24
- Christopher J. Halbrook · 1 shared paper, 2026 · strength 0.20
- Alexander Muir · 1 shared paper, 2026 · strength 0.20
- Jennifer Brooke Valerin · 1 shared paper, 2026 · strength 0.20
- Chantal Allgöwer · 1 shared paper, 2026 · strength 0.20
- Austin D. Silva · 1 shared paper, 2026 · strength 0.20
- Tim Eiseler · 1 shared paper, 2026 · strength 0.20
- Rima Singh · 1 shared paper, 2026 · strength 0.20
- Alica K. Michels · 1 shared paper, 2026 · strength 0.20
- Alexander Kleger · 1 shared paper, 2026 · strength 0.20
- Thomas Theodor Werner Seufferlein · 1 shared paper, 2026 · strength 0.20
- Aimee L Edinger · 1 shared paper, 2026 · strength 0.20
- David Kuang-Fu Chang · 1 shared paper, 2026 · strength 0.20
- Divya Sood · 1 shared paper, 2025 · strength 0.17
- Bharti Garg · 1 shared paper, 2025 · strength 0.17
- Nirakar Rajbhandari · 1 shared paper, 2025 · strength 0.17
- Pnina Brodt · 1 shared paper, 2025 · strength 0.17
- Dawn Jaquish · 1 shared paper, 2025 · strength 0.17
- Cosimo Commisso · 1 shared paper, 2025 · strength 0.17
- Steve Gallinger · 1 shared paper, 2025 · strength 0.17
- Satoshi Ogawa · 1 shared paper, 2023 · strength 0.16
- Jonathan Weitz · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.